SC Summons Patanjali MD Acharya Balakrishna and Co-founder Baba Ramdev in Contempt Case Over Misleading Medical Ads
In its order, the court not only summoned Acharya Balakrishna but also issued a contempt notice to Baba Ramdev, citing prima facie violations of Section 3 and 4 of the Drugs and Magic Remedies Act.
In a significant development, the Supreme Court has ordered the personal appearance of Acharya Balakrishna, the Managing Director of Patanjali Ayurved, and Baba Ramdev, the renowned yoga guru and co-founder of the company. This decision came as a response to a contempt case filed against Patanjali Ayurved and its leadership for persisting in publishing misleading advertisements related to medicinal cures.
The bench comprising of Justices Hima Kohli and Ahsanuddin Amanullah presided over the hearing of the case. The court had previously issued a contempt notice to Patanjali Ayurved and its Managing Director for disregarding assurances made to the court last November. At that time, Patanjali’s counsel had pledged to refrain from disseminating such misleading advertisements.
Despite the assurances, the court noted with concern that Patanjali continued its misleading advertising practices, prompting the bench to take stern action. Today’s proceedings revealed that Patanjali had failed to file a reply to the contempt notice, leading the bench to escalate the matter further.
In its order, the court not only summoned Acharya Balakrishna but also issued a contempt notice to Baba Ramdev, citing prima facie violations of Sections 3 and 4 of the Drugs and Magic Remedies Act. This move underscores the court’s determination to uphold the integrity of medical advertising regulations and hold accountable those who flout them.
The court’s decision to summon the top leadership of Patanjali reflects the gravity of the situation and sends a strong message regarding the importance of compliance with regulatory standards, particularly in the sensitive area of healthcare. The personal appearance of Acharya Balakrishna and Baba Ramdev before the court is expected to shed light on the company’s advertising practices and its commitment to adhering to legal and ethical norms.
This development comes amidst growing scrutiny of the advertising practices of companies operating in the health and wellness sector. Misleading claims regarding medicinal products not only deceive consumers but also pose risks to public health and undermine trust in the healthcare system.
As the case progresses, all eyes will be on the Supreme Court as it seeks to address the issue of misleading medical advertisements and ensure accountability in the industry. The outcome of this case could have far-reaching implications for the regulation of healthcare advertising in the country, setting a precedent for future cases and shaping the conduct of companies operating in this sector.
